Natixis Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $80.6M | Buy |
129,236
+3,563
| +3% | +$2.43M | 0.09% | 198 |
|
|
2026
Q1 | $97.1M | Buy |
125,673
+3,085
| +3% | +$2.36M | 0.14% | 158 |
|
|
2025
Q4 | $94.6M | Buy |
122,588
+2,479
| +2% | +$1.68M | 0.13% | 157 |
|
|
2025
Q3 | $67.5M | Buy |
120,109
+7,084
| +6% | +$4.01M | 0.1% | 201 |
|
|
2025
Q2 | $59.3M | Sell |
113,025
-3,207
| -3% | -$1.79M | 0.09% | 222 |
|
|
2025
Q1 | $73.7M | Buy |
116,232
+6,294
| +6% | +$4.33M | 0.14% | 166 |
|
|
2024
Q4 | $78.3M | Sell |
109,938
-7,064
| -6% | -$5.93M | 0.15% | 142 |
|
|
2024
Q3 | $123M | Buy |
117,002
+319
| +0.3% | +$355K | 0.24% | 94 |
|
|
2024
Q2 | $123M | Buy |
116,683
+2,720
| +2% | +$2.64M | 0.27% | 83 |
|
|
2024
Q1 | $110M | Buy |
113,963
+3,546
| +3% | +$3.37M | 0.25% | 94 |
|
|
2023
Q4 | $97M | Sell |
110,417
-604
| -0.5% | -$497K | 0.26% | 95 |
|
|
2023
Q3 | $91.4M | Sell |
111,021
-123
| -0.1% | -$96.7K | 0.28% | 85 |
|
|
2023
Q2 | $79.9M | Sell |
111,144
-859
| -0.8% | -$662K | 0.25% | 100 |
|
|
2023
Q1 | $92M | Buy |
112,003
+4,588
| +4% | +$3.46M | 0.32% | 79 |
|
|
2022
Q4 | $77.5M | Sell |
107,415
-27,451
| -20% | -$20.3M | 0.29% | 93 |
|
|
2022
Q3 | $92.9M | Sell |
134,866
-326
| -0.2% | -$205K | 0.39% | 56 |
|
|
2022
Q2 | $79.9M | Sell |
135,192
-40,701
| -23% | -$26.5M | 0.35% | 70 |
|
|
2022
Q1 | $123M | Sell |
175,893
-5,398
| -3% | -$3.42M | 0.47% | 38 |
|
|
2021
Q4 | $114M | Sell |
181,291
-71,561
| -28% | -$44M | 0.44% | 45 |
|
|
2021
Q3 | $153M | Buy |
252,852
+115,720
| +84% | +$71.8M | 0.63% | 25 |
|
|
2021
Q2 | $76.6M | Sell |
137,132
-1,206
| -0.9% | -$611K | 0.36% | 55 |
|
|
2021
Q1 | $65.5M | Sell |
138,338
-5,075
| -4% | -$2.47M | 0.34% | 58 |
|
|
2020
Q4 | $69.3M | Sell |
143,413
-43,123
| -23% | -$23.3M | 0.4% | 49 |
|
|
2020
Q3 | $104M | Sell |
186,536
-7,972
| -4% | -$4.83M | 0.66% | 23 |
|
|
2020
Q2 | $121M | Sell |
194,508
-14,786
| -7% | -$8.39M | 0.81% | 17 |
|
|
2020
Q1 | $102M | Buy |
209,294
+624
| +0.3% | +$257K | 0.83% | 17 |
|
|
2019
Q4 | $78.4M | Sell |
208,670
-1,722
| -0.8% | -$579K | 0.55% | 34 |
|
|
2019
Q3 | $58.4M | Buy |
210,392
+3,523
| +2% | +$1.04M | 0.46% | 46 |
|
|
2019
Q2 | $64.8M | Buy |
206,869
+471
| +0.2% | +$157K | 0.53% | 38 |
|
|
2019
Q1 | $84.8M | Buy |
206,398
+7,309
| +4% | +$3.01M | 0.74% | 19 |
|
|
2018
Q4 | $74.4M | Sell |
199,089
-7,161
| -3% | -$2.62M | 0.73% | 25 |
|
|
2018
Q3 | $83.3M | Buy |
206,250
+16,826
| +9% | +$6.4M | 0.73% | 19 |
|
|
2018
Q2 | $65.3M | Buy |
189,424
+10,649
| +6% | +$3.33M | 0.62% | 22 |
|
|
2018
Q1 | $61.6M | Buy |
178,775
+46,611
| +35% | +$16.2M | 0.61% | 27 |
|
|
2017
Q4 | $49.7M | Buy |
132,164
+4,130
| +3% | +$1.67M | 0.51% | 40 |
|
|
2017
Q3 | $57.2M | Sell |
128,034
-4,965
| -4% | -$2.36M | 0.6% | 30 |
|
|
2017
Q2 | $65.3M | Buy |
132,999
+3,779
| +3% | +$1.65M | 0.71% | 22 |
|
|
2017
Q1 | $50.1M | Buy |
129,220
+23,324
| +22% | +$8.65M | 0.55% | 33 |
|
|
2016
Q4 | $38.9M | Buy |
105,896
+35,479
| +50% | +$13.5M | 0.47% | 43 |
|
|
2016
Q3 | $28.3M | Buy |
+70,417
| New | +$28.2M | 0.37% | 53 |
|
|
2014
Q3 | – | Sell |
-6,962
| Closed | -$1.97M | – | 1180 |
|
|
2014
Q2 | $1.97M | Buy |
6,962
+1,082
| +18% | +$321K | 0.03% | 653 |
|
|
2014
Q1 | $1.77M | Buy |
5,880
+4,837
| +464% | +$1.49M | 0.03% | 643 |
|
|
2013
Q4 | $287K | Buy |
1,043
+90
| +9% | +$25.9K | ﹤0.01% | 1029 |
|
|
2013
Q3 | $299K | Buy |
+953
| New | +$251K | 0.01% | 975 |
|
Other funds holding REGN
Natixis Advisors's REGN Position: Q2 2026 in Review
Natixis Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 2.8% in Q2 2026, buying an estimated $2.43M and bringing the position to 129,236 shares worth $80.6M. The position accounts for 0.09% of the portfolio, ranked #198.
Natixis Advisors first reported a position in REGN in Q3 2013 and has held it in 44 quarters since. The position peaked at $153M in Q3 2021. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Natixis Advisors held 129,236 shares of Regeneron Pharmaceuticals worth $80.6M as of Q2 2026.
- Natixis Advisors bought 3,563 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.43M.
- Regeneron Pharmaceuticals made up 0.09% of Natixis Advisors's portfolio in Q2 2026, its #198 holding.
- Natixis Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 44 quarters since.
- Natixis Advisors's Regeneron Pharmaceuticals position peaked at $153M in Q3 2021.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.